Periodontal Disease Drug Pipeline Analysis Report 2025

Periodontal disease, a chronic inflammatory condition affecting the gums and supporting structures of teeth, is estimated to impact around 19% of the global adult population, with over 1 billion cases worldwide. Despite the availability of current treatment options, such as scaling and root planing, these therapies fail to address the underlying causes or provide long-term relief, highlighting a significant unmet clinical need. The growing focus on regenerative medicine, advanced biomaterials, and targeted therapies is expected to drive pipeline growth, offering hope for more effective treatments and improved patient outcomes in the coming years.

Report Coverage

The Periodontal Disease Drug Pipeline Insight Report by the publisher gives comprehensive insights into periodontal disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for periodontal disease. The periodontal disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The periodontal disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with periodontal disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to periodontal disease.

Periodontal Disease Drug Pipeline Outlook

Periodontal disease is an inflammatory condition that affects the tissues surrounding and supporting the teeth, caused by bacterial infections that lead to gum recession, tooth loss, and bone destruction. It occurs due to poor oral hygiene, smoking, and genetic factors. The condition progresses through stages, from gingivitis to severe periodontitis, causing irreversible damage if untreated.

Periodontal disease treatment focuses on controlling infection and halting disease progression. Conventional treatments include scaling and root planing, along with surgical interventions for severe cases. Emerging therapies target inflammation reduction, tissue regeneration, and bacterial management, aiming to offer more effective, long-lasting solutions.

Periodontal Disease Epidemiology

Severe periodontal disease affects approximately 19% of the global adult population, equating to over 1 billion cases worldwide. In the United States, nearly 50% of adults experience some form of the disease, while in India, the prevalence among adults reaches 51%. This widespread impact underscores the critical need for innovative therapies in the pipeline.

Periodontal Disease Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of periodontal disease drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Peptides-Based Therapies
• Gene Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Periodontal Disease Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III holds a major share of the total periodontal disease clinical trials.

Periodontal Disease - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the periodontal disease pipeline analysis include small molecules, biologics, peptide- based therapies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for periodontal disease.

Periodontal Disease Clinical Trials Therapeutic Assessment - Competitive Dynamics

The periodontal disease drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in periodontal disease clinical trials:

• Colgate Palmolive
• Bausch Health Companies Inc.
• Lyne Laboratories
• Xttrium Laboratories
• Dentsply Sirona Inc.
• Biolase, Inc.

Periodontal Disease Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for periodontal disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of periodontal disease drug candidates.

Drug: Chlorhexidine Toothpaste

Colgate Palmolive is sponsoring a Phase III clinical study to evaluate the effect of a toothpaste containing 0.3% chlorhexidine in subjects with established gingivitis, which is early stage of periodontal disease. The objective of this study is to assess the reduction of gingival inflammation, a key factor in periodontal disease progression. The study is expected to be completed by April 2025, with around 80 participants enrolled.

Drug: Human Dental Pulp Stem Cells

The Phase 2 clinical trial, sponsored by Peking University Third Hospital, focuses on evaluating the efficacy and safety of human dental pulp mesenchymal stem cells (hDP-MSCs) for treating periodontal disease, specifically chronic periodontitis. This randomized, double-blind, placebo-controlled study aims to assess the impact of different administration protocols on patient outcomes. The trial, involving about 204 participants, is expected to be completed by September 2026.

Drug: Bromelain Gel

Sponsored by Krishnadevaraya College of Dental Sciences & Hospital, this Phase 1 study aims to evaluate the effectiveness of Bromelain gel following scaling and root planing (SRP). It is expected to be completed in July 2025, with an estimated 36 participants.

Reasons To Buy This Report

The Periodontal Disease Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for periodontal disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into periodontal disease collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Periodontal Disease - Pipeline Insight Report

• Which companies/institutions are leading the periodontal disease drug development?
• What is the efficacy and safety profile of periodontal disease pipeline drugs?
• Which company is leading the periodontal disease pipeline development activities?
• What is the current periodontal disease commercial assessment?
• What are the opportunities and challenges present in the periodontal disease drug pipeline landscape?
• What is the efficacy and safety profile of periodontal disease pipeline drugs?
• Which company is conducting major trials for periodontal disease drugs?
• Which companies/institutions are involved in periodontal disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in periodontal disease?

This product will be delivered within 3-5 business days.